Literature DB >> 20590552

Number of prostate cancer risk alleles may identify possibly 'insignificant' disease.

Brian T Helfand1, Stacy Loeb, Donghui Kan, William J Catalona.   

Abstract

OBJECTIVE: To determine whether the cumulative effects of five prostate cancer risk alleles (three single-nucleotide polymorphisms [SNPs] on chromosome 8Q24 and two SNPs on chromosome 17a) could help to identify possibly 'insignificant' disease.
MATERIALS AND METHODS: We genotyped 629 men of European ancestry who underwent radical prostatectomy at our institution between 2002 and 2007. Possibly 'insignificant' CaP was defined using the Ohori criteria (organ-confined, tumour volume <0.5 mL, Gleason pattern ≤4). Statistical analysis was used to compare patients with 'insignificant' and all other 'significant' cancer based upon genotype. Carrier status for the 5 SNPs were compared between patients with 'insignificant' disease and a separate population of 801 controls without CaP.
RESULTS: Overall, 38 (6.0%) patients with CaP met the Ohori criteria for 'insignificant' disease. Men with 'significant' cancer had a greater frequency of any of the five risk alleles than either patients with 'insignificant' disease or controls. None of the individual alleles genotyped on chromosomes 8 or 17 distinguished between 'significant' and 'insignificant' CaP. However, carriers of two or more risk alleles were more likely to have 'significant' disease.
CONCLUSIONS: Although no single risk allele distinguished 'insignificant' CaP, 'insignificant' disease was nearly three times as likely among carriers of ≤ one risk allele. Future studies are needed to further elucidate the cumulative relationship between CaP risk alleles and CaP aggressiveness.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 20590552      PMCID: PMC3072834          DOI: 10.1111/j.1464-410X.2010.09440.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  29 in total

1.  A common variant associated with prostate cancer in European and African populations.

Authors:  Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2006-05-07       Impact factor: 38.330

2.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

Authors:  Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

3.  Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Authors:  Prodipto Pal; Huifeng Xi; Saurav Guha; Guangyun Sun; Brian T Helfand; Joshua J Meeks; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

4.  Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.

Authors:  Y Goto; M Ohori; A Arakawa; M W Kattan; T M Wheeler; P T Scardino
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.

Authors:  Jianfeng Xu; Siqun Lilly Zheng; Sarah D Isaacs; Kathleen E Wiley; Fredrik Wiklund; Jielin Sun; A Karim Kader; Ge Li; Lina D Purcell; Seong-Tae Kim; Fang-Chi Hsu; Pär Stattin; Jonas Hugosson; Jan Adolfsson; Patrick C Walsh; Jeffrey M Trent; David Duggan; John Carpten; Henrik Grönberg; William B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

Review 7.  A systematic review and meta-analysis of familial prostate cancer risk.

Authors:  L E Johns; R S Houlston
Journal:  BJU Int       Date:  2003-06       Impact factor: 5.588

8.  Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.

Authors:  Brian T Helfand; Stacy Loeb; John Cashy; Joshua J Meeks; C Shad Thaxton; Misop Han; William J Catalona
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

9.  Pathological outcomes associated with the 17q prostate cancer risk variants.

Authors:  Brian T Helfand; Stacy Loeb; Joshua J Meeks; Angela J Fought; Donghui Kan; William J Catalona
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

10.  Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.

Authors:  Kathryn L Penney; Claudia A Salinas; Mark Pomerantz; Fredrick R Schumacher; Christine A Beckwith; Gwo-Shu Lee; William K Oh; Oliver Sartor; Elaine A Ostrander; Tobias Kurth; Jing Ma; Lorelei Mucci; Janet L Stanford; Philip W Kantoff; David J Hunter; Meir J Stampfer; Matthew L Freedman
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

View more
  5 in total

1.  Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance.

Authors:  Barry B McGuire; Brian T Helfand; Shilajit Kundu; Qiaoyan Hu; Jessica A Banks; Phillip Cooper; William J Catalona
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Authors:  Brian T Helfand; Kimberly A Roehl; Phillip R Cooper; Barry B McGuire; Liesel M Fitzgerald; Geraldine Cancel-Tassin; Jean-Nicolas Cornu; Scott Bauer; Erin L Van Blarigan; Xin Chen; David Duggan; Elaine A Ostrander; Mary Gwo-Shu; Zuo-Feng Zhang; Shen-Chih Chang; Somee Jeong; Elizabeth T H Fontham; Gary Smith; James L Mohler; Sonja I Berndt; Shannon K McDonnell; Rick Kittles; Benjamin A Rybicki; Matthew Freedman; Philip W Kantoff; Mark Pomerantz; Joan P Breyer; Jeffrey R Smith; Timothy R Rebbeck; Dan Mercola; William B Isaacs; Fredrick Wiklund; Olivier Cussenot; Stephen N Thibodeau; Daniel J Schaid; Lisa Cannon-Albright; Kathleen A Cooney; Stephen J Chanock; Janet L Stanford; June M Chan; John Witte; Jianfeng Xu; Jeannette T Bensen; Jack A Taylor; William J Catalona
Journal:  Hum Genet       Date:  2015-02-26       Impact factor: 4.132

3.  Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.

Authors:  Jeannette T Bensen; Zongli Xu; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jack A Taylor
Journal:  Prostate       Date:  2012-05-01       Impact factor: 4.104

Review 4.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

5.  Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.

Authors:  Yu Zhang; Na Zeng; Yi Chen Zhu; Yang Xin Rui Huang; Qiang Guo; Ye Tian
Journal:  World J Surg Oncol       Date:  2018-06-01       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.